Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression
Citations Over TimeTop 10% of 2015 papers
Abstract
Quantitation of huntingtin protein in the brain is needed, both as a marker of Huntington disease (HD) progression and for use in clinical gene silencing trials. Measurement of huntingtin in cerebrospinal fluid could be a biomarker of brain huntingtin, but traditional protein quantitation methods have failed to detect huntingtin in cerebrospinal fluid. Using micro-bead based immunoprecipitation and flow cytometry (IP-FCM), we have developed a highly sensitive mutant huntingtin detection assay. The sensitivity of huntingtin IP-FCM enables accurate detection of mutant huntingtin protein in the cerebrospinal fluid of HD patients and model mice, demonstrating that mutant huntingtin levels in cerebrospinal fluid reflect brain levels, increasing with disease stage and decreasing following brain huntingtin suppression. This technique has potential applications as a research tool and as a clinical biomarker.
Related Papers
- → Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease(2007)112 cited
- → Impaired mitochondrial trafficking in Huntington's disease(2009)67 cited
- → Recent Trends in Detection of Huntingtin and Preclinical Models of Huntington’s Disease(2014)5 cited
- → Inhibition of caspase-6: A potential therapy for Huntington’s disease(2008)
- Assessments of potential interactions of huntingtin-associated-protein-1 in the R6/2 mouse model of Huntington's disease(2004)